P3, N=1300, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2029 --> Dec 2027 | Trial primary completion date: Dec 2029 --> Dec 2027

20 hours ago

Trial completion date • Trial primary completion date

Ocrevus (ocrelizumab)

CONSONANCE: A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (clinicaltrials.gov)

P3, N=927, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Jan 2026 --> Nov 2026

2 days ago

Trial primary completion date

Ocrevus (ocrelizumab)

13d

WINDOCRE: Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial (clinicaltrials.gov)

P3, N=244, Recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Trial completion date: Nov 2027 --> Nov 2029 | Trial primary completion date: Nov 2027 --> Nov 2029

13 days ago

Trial completion date • Trial primary completion date • Head-to-Head

Ocrevus (ocrelizumab)

28d

MUSCAT: A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov)

P3, N=292, Recruiting, Biocad

28 days ago

New P3 trial

Ocrevus (ocrelizumab)

Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation (clinicaltrials.gov)

P4, N=22, Completed, Massachusetts General Hospital | Not yet recruiting --> Completed | Trial completion date: Jul 2022 --> Apr 2025

1 month ago

Trial completion • Trial completion date

Ocrevus (ocrelizumab)

2ms

Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)

P2, N=360, Not yet recruiting, Hoffmann-La Roche

2 months ago

New P2 trial

Ocrevus (ocrelizumab)

2ms

Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases. (PubMed, Ther Adv Neurol Disord)

The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation...However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.

2 months ago

Journal

IL6R (Interleukin 6 receptor)

Rituxan (rituximab) • cyclophosphamide • methotrexate • Campath (alemtuzumab) • mitoxantrone • cladribine • Arzerra (ofatumumab) • Briumvi (ublituximab-xiiy) • fingolimod • Actemra IV (tocilizumab) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)

2ms

BI26 More than skin deep: a case of eosinophilic fasciitis in a patient with relapsing-remitting multiple sclerosis. (PubMed, Br J Dermatol)

Her disease remains well controlled on methotrexate 15 mg once weekly. While the development of eosinophilic fasciitis in this case was presumed to be idiopathic, to our knowledge, this is the first case of eosinophilic fasciitis developing in the setting of long-term ocrelizumab use.

2 months ago

Journal

CRP (C-reactive protein)

methotrexate • Ocrevus (ocrelizumab)

2ms

Effects of Ocrevus in Relapsing Multiple Sclerosis (clinicaltrials.gov)

P4, N=60, Active, not recruiting, Georgia State University | Trial completion date: Sep 2025 --> Dec 2025

2 months ago

Trial completion date

Ocrevus (ocrelizumab)

2ms

Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor. (PubMed, Int J Mol Sci)

This result implies that PBMCs' TNF mRNA expression might be potentially considered as a prognostic biomarker of ocrelizumab effectiveness in MS patients. However, further studies comprising large cohorts and additional immunological parameters are warranted.

2 months ago

Journal • Gene Expression Profile

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD86 (CD86 Molecule)

Ocrevus (ocrelizumab)

2ms

BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab. (PubMed, J Neuroinflammation)

This study provides insight into unique biomarker profile in patients on ocrelizumab. Increased BAFF was associated with lower IgG and IgA levels, biomarkers of neuroaxonal damage and inflammation in MS patients without recent acute inflammatory activity on ocrelizumab.

2 months ago

Journal

SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL20 (C-C Motif Chemokine Ligand 20) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TNFRSF10A (TNF Receptor Superfamily Member 10a) • CDCP1 (CUB Domain Containing Protein 1) • GFAP (Glial Fibrillary Acidic Protein) • NEFL (Neurofilament Light Chain)

Ocrevus (ocrelizumab)

2ms

Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy (clinicaltrials.gov)

P=N/A, N=111, Not yet recruiting, Region Stockholm | Initiation date: Oct 2025 --> Feb 2026

2 months ago

Trial initiation date

Rituxan (rituximab) • Ocrevus (ocrelizumab)